RAJ MANCHANDA, Ph.D.
Chief Development Officer
Raj is the Chief Development Officer for Frequency Therapeutics. Prior to joining Frequency, Raj was Vice President of Neurodegeneration Asset Development for Biogen. While at Biogen, he was instrumental in leading the CMC development for approval and commercialization for Tecfidera™, the leading oral therapy for MS. Before Biogen, he led development of imaging agents for Alzheimer’s at Avid Radiopharmaceuticals, which was acquired by Eli Lilly and Company in 2010. Previously, Raj has held key R&D positions at PerkinElmer and Diatide, which was acquired by Schering AG in 1999. During his 20 years in the pharmaceutical industry, he has worked on over 25 INDs and 6 NDAs, including two drug development programs that received Fast Track designation from the U.S. Food and Drug Administration. He has provided program management for drug development in infectious disease, CNS, oncology, immunology and imaging. Raj holds a Ph.D. in Chemistry from Yale University and was an Anna Fuller postdoctoral fellow at MIT. Raj has also completed the Advanced Management Program from the Sloan School of Management at MIT